In order to help ensure that biologics are being used with the right patients at the right time, reimbursement for these medications has been subject to insurance policies (e.g., prior authorization and step therapy). Utilization management criteria may not be known to patients and physicians when starting therapy and therefore, they may experience a delay in initiating therapy, be required to receive a different medication, or never receive the medication. In addition, patients and physicians may choose to delay or change therapy for a number of other reasons. Significantly delaying receipt of necessary medications could lead to worsened disease activity over time.
Objectives
The goal of this study was to quantify the delay from when a prescription was written for a biologic or conventional DMARD until the patient first received either the intended medication or a different medication in the same class. optum.com
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Methods
This was a retrospective analysis using the Optum ® Research Database (ORD), which includes normalized data from electronic health records (EHR) deterministically linked with medical and pharmacy claims data from a large managed care organization affiliated with Optum. Patients with at least one prescription written for a biologic DMARD (adalimumab, abatacept, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib) or a conventional DMARD (hydroxychloroquine, leflunomide, methotrexate or sulfasalazine) between January 2008 and December 2014 were identified from the EHR database.
The earliest prescription written during the identification period was considered the index prescription. In order to maximize the available sample size of the biologically treated cohort, patients with prescriptions for both biologic and conventional DMARDs during the identification period had their index date set as the date of the first prescription written for the biologic agent. Patients were retained in the study if the index prescription was considered a new prescription, the patient was diagnosed with an inflammatory condition, and the patient had two years of claims data available (one year prior and one year following the index date). For prescriptions to be classified as new, patients needed to have clinical activity in the EHR for at least one year before the date the index prescription was written, and they could not have a prescription written for the same medication in the year before. Patients whose index prescription was for a biologic DMARD could have prescriptions written for conventional DMARDs during the baseline. Inflammatory conditions included RA, PsO, PsA, AS, CD or UC. Patients were considered to have claims data available if they were enrolled in a commercial or Medicare Advantage health plan with medical and pharmacy benefits with no gaps in therapy greater than 31 days long.
The main outcomes for this study included receipt of the index medication during the one-year baseline, receipt of the index medication or a similar medication during the one-year follow up, and the number of days from the first prescription written until the first receipt of medication. The timing of the receipt of medication was calculated as a continuous measure and a categorical measure (for example, before the index prescription was written, on the index date, or after the index date). Medications were considered similar but different if they were within the same class (biologic or conventional), but were for a different compound. For example, if the patient's index prescription written was for etanercept, but the first biologic received was adalimumab. All biologic agents were considered similar to each other, and all conventional DMARDs were considered similar to each other. No distinction was made between routes of administration (for example, IV vs. SC). Table 1 describes the sample attrition after applying each of the inclusion and exclusion criteria. The primary criteria (steps 1, 2, 4, 7 and 8) are highlighted, however, additional criteria were necessary in order to refine the sample and implement deterministic matching criteria. There were more than 221,000 patients who had a diagnosis of an inflammatory condition between January 1, 2008, and December 31, 2014, of which 55,603 had a prescription written for a biologic or conventional DMARD. A total of 38,895 patients had at least one year of EHR activity before the index prescription was written. There were 4,776 enrolled patients in the claims data that overlapped the index date, and 2,715 patients were enrolled for at least one year before through one year after the index date. The final sample was 2,710, after excluding five patients whose index date occurred during an inpatient stay (1,229 biologic cohort and 1,481 conventional cohort).
Results

Main outcomes for study:
• Receipt of the index medication during the oneyear baseline
• Receipt of the index medication or a similar medication during the oneyear follow-up
• The number of days from the first prescription written until the first receipt of medication A little more than half of the patients in both cohorts received the index medication before the index prescription was written (54.8 percent biologic and 52.2 percent conventional). In addition, approximately 10 percent of patients in both cohorts (9.5 percent biologic and 11.6 percent conventional) had no fills/infusions for either the index medication or a similar medication during the one-year follow up. The remaining 39 percent of patients in each cohort received either the index medication or a similar medication on or within one year of the index prescription being written. The 38.5 percent of biologic patients was composed of 10.1 percent of patients who experienced no delay, and 28.4 percent of patients who experienced a delay. In the conventional cohort, these percentages are reversed -28.9 percent did not experience a delay, and 10.3 percent did experience a delay. In both cohorts, when patients received the medication on the same day that the prescription was written, it was typically for the index medication and not a similar medication. However, for patients who did experience a delay in therapy, there was a propensity to receive a different medication. In the biologic cohort, 17.2 percent of patients who experienced a delay eventually received a medication different from the index medication. In the conventional cohort, 5.6 percent eventually received a different medication.
The delay in receiving a medication was also examined excluding patients who either received the index medication before the prescription was written, or who never received a medication during the one-year follow up. The remaining sample comprised 438 patients in the biologic cohort and 536 patients in the conventional cohort. The mean delay in the biologic cohort was 25.0 days, compared with 10.5 days in the conventional cohort (P<0.001). In the biologic cohort, 28.3 percent of patients experienced no delay, compared to almost 80 percent in the conventional cohort. In the biologic cohort, 22.8 percent experienced a delay of one to seven days, 29 percent had a delay of eight to 30 days, and 19.9 percent had a delay of over 30 days. The delay in receiving a biologic was calculated among the 438 patients who had a prescription written for a biologic, received a biologic within a year of the prescription, and did not receive the index medication before the date of the index prescription. The length of the delay was then stratified by whether the patient actually received the index medication, versus a different biologic. Patients who received the index medication had a mean delay of 20.9 days, versus 51.7 days for patients who received a different biologic. Almost one-third of patients who received the index biologic experienced no delay, versus only 6.9 percent of patients who received a different biologic. A total of 36.2 percent of patients who received a different biologic experienced a delay of over a month, versus 17.4 percent of patients who received the index medication.
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Discussion
For patients with inflammatory conditions who have moderate to severe disease activity, treatment with biologics may be necessary. However, in recent years, the cost of these medications has increased significantly. Because of this increased cost, health plans have instituted policies that limit reimbursement of these medications, and patients may also choose to delay or forgo therapy. This study aimed to quantify the length of the delay and to identify characteristics associated with longer delays.
This study used a novel linkage of clinical data from EHRs with claims data. Over half of patients either filled or were infused with the index medication before the index prescription was written, which may indicate that most patients' index prescription was actually for a reorder of a medication that they were already treated with. There were also about 10 percent of patients who did not receive the index medication (or a similar medication) within one year of the index prescription being written. The observed delay among the remaining patients highlights two key findings. First, patients in the biologic cohort were more likely than patients in the conventional cohort to experience a delay, and to have longer delays. Second, patients in the biologic cohort who received the index medication had shorter and fewer delays than patients who received a different biologic.
It should be noted that the exact reason for the delay is unknown, and while health plans have instituted prior authorization and step therapy policies, patients may choose to delay therapy even when they are authorized to receive the medication. However, given that longer delays were observed for biologic medications compared to conventional medications, this may indicate that health plan policies impact how quickly a patient can receive a biologic.
Conclusion
Patients treated with biologics were more likely to experience a delay in receiving therapy compared to patients treated with conventional DMARDs, and the average delay was approximately four weeks. Among users of biologics, patients who received the same medication as the index prescription had fewer and shorter delays than patients who received a biologic different than the index prescription.
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